The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates,

Slides:



Advertisements
Similar presentations
Introduction Treatment of metastatic prostate cancer with androgen deprivation therapy (ADT) is effective, but can be associated with debilitating side.
Advertisements

Copyright ©2008 Accuray, Incorporated. All rights reserved E CyberKnife ® Robotic Radiosurgery System Radiosurgery System Comparisons.
Department of Radiation Oncology. Facilities Available 3 Linear Accelerators Namely 1. Novalis Tx with 2 photon and 6 Electron beems. OBI and RPM – Gating.
CyberKnife®: Tumor Removal
The TrueBeam System ™ Clinic Name Presenter’s name Clinic location
Advanced Practice in Radiotherapy
Stereotactic Radiosurgery Jimmy Johannes Physics 335 – Spring 2004 Final Presentation
Stereotactic RadiologyStereotactic Radiology By: Jeremy Lishner.
Innovation/Impact: By designing a simulated human shaped (anthropomorphic) plastic phantom with targets, organs at risk (OAR) and heterogeneities, the.
Stereotactic Body Radiation Therapy (SBRT): The optimal indication for operable tumors in inoperable patients D.Katsochi 1, S.Kosmidis 1, A.Fotopoulou.
The Health Roundtable 1-1b_HRT1215-Session_HEGI_JOHNSON_WESTMEAD_NSW Volumetric Modulated Arc Therapy for Stereotactic Body Radiotherapy in Early Lung.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Radiation and Prostate Cancer Past, Present and Future Dr
CET Cancer Center Oakland California High Dose Rate (HDR) Brachytherapy Gynecological Cancer D. Jeffrey Demanes M.D
Autonomous Robotics in Medicine Michael Saracen February 11, 2009.
Mariah Cordie and Deb Norrell. What is CyberKnife?  World’s first and only robotic radiosurgery system designed to treat tumors throughout the body non-
Comparison of Rectal Dose Volume Histograms for Definitive Prostate Radiotherapy Among Stereotactic Radiotherapy, IMRT, and 3D-CRT Techniques Author(s):
Conclusions HDR brachytherapy boost combined with moderate dose external beam irradiation resulted in a very high local control rate and few recurrences.
Prof Stephen Langley Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey Focal Brachytherapy UK experience.
Decreased Risk of Radiation Pneumonitis With Coincident Concurrent Use Of Angiotensin- Converting Enzyme Inhibitors In Patients Receiving Lung Stereotactic.
Radiologic Assessment of the Genitourinary Diaphragm Using MRI with Endorectal Coil in Men with Localized Prostate Cancer ASTRO Annual Meeting 2014, #3792.
Learn More At: CyberKnife Radiosurgery in the Treatment of Early and Advanced (Oligo-Metastases) Breast Cancer Sandra Vermeulen,
Ten Year Outcomes In Men Under 60 Treated With Iodine-125 Permanent Brachytherapy As Monotherapy GU - Prostate Cancer: Novel Imaging (MRI,PET) & Brachytherapy.
PROSTATE CANCER: RADIATION THERAPY APPROACHES ANDREW L. SALNER, MD FACR DIRECTOR HELEN & HARRY GRAY CANCER CENTER HARTFORD HOSPITAL, CT.
Comparison of Toxicity Profiles Associated with Three High-Dose-Rate Brachytherapy Treatment Schedules for Favorable-Risk Prostate Cancer Maha Saada Jawad,
The Radiological Physics Center’s Anthropomorphic Quality Assurance Phantom Program Carrie F. Amador, Nadia Hernandez, Andrea Molineu, Paola Alvarez, and.
Corresponding author Name; 2015 North Jefferson St; Three-Year Analysis of Urinary Toxicity in Two Prospective Trials.
Michael Brada Torino 6 March 2015 Perspectives in lung cancer Stereotactic ablative radiation therapy (SABR) in patients with inoperable NSCLC.
High Dose Rate Brachytherapy Boost for Prostate Cancer: Comparison of Two Different Fractionation Schemes Tania Kaprealian 1, Vivian Weinberg 3, Joycelyn.
Gamma Knife Kelly & Tarah.
Understanding Prostate Myths
David Spellberg M.D., FACS
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates,
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
HIFU AND CRYOSURGERY David Spellberg M.D., FACS.
Stereotactic Body Radiation Therapy for Early Stage Prostate Cancer: Outcomes from a Single Institution Study Stereotactic Body Radiation Therapy for Early.
Debra Freeman, MD – Naples Christopher King, MD, PhD - Stanford.
David Spellberg, M.D., FACS Naples Urology Associates, P.A.
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Stereotactic Body Radiation Therapy: An Emerging Treatment Approach for Early Stage Prostate Cancer Stereotactic Body Radiation Therapy: An Emerging Treatment.
Cyberknife Therapy for Prostate Cancer David Spellberg M.D., FACS Naples Urology Associates, P.A.
Dose Calculations for Cyberknife Stereotactic Body Radiation Therapy For CK, one can fractionate the therapy yet remain convenient and non-invasive for.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS.
Radiation therapy for Early Stage Prostate Cancer
INTRODUCTION RESULTS DATA ANALYSIS DISCUSSION METHODS REFERENCES
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Prostate Cancer Jay L. Friedland, MD.
Left Posterior Superior Right Anterior Inferior
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized and Advanced Prostate Cancer David M. Spellberg M.D., FACS Naples.
Figure 1. The (a) anterior–posterior and (b) right-lateral fields and (c, d) the isodose distributions of two axial planes in one patient with T2 stage.
Evaluation of biologically equivalent dose escalation, clinical outcome, and toxicity in prostate cancer radiotherapy: A meta-analysis of 12,000 patients.
Insert tables Insert graphs Insert figure
Impact of magnetic resonance imaging on computed tomography-based treatment planning and acute toxicity for prostate cancer patients treated with intensity.
Insert tables Insert graphs Insert figure
CK RS for non-resectable pancreatic tumors
One in every 14 patients with early-stage lung cancer is not being treated!  Benny Weksler, MD, MBA  The Journal of Thoracic and Cardiovascular Surgery 
European Urology Oncology
Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization 
Figure 4 Dosimetric comparison of LDR‑BT versus HDR‑BT
Oncology Market Forecast
Figure 2 Nonmalignant tissue can be spared from radiation
Figure 4 Treatment plans using stereotactic body radiotherapy (SBRT)
Radiation Therapy for Prostate Cancer
ML 291 Rev. A.
Efficacy of fiducial marker-based image-guided radiation therapy in prostate tomotherapy and potential dose coverage improvement using a patient positioning.
Clinical and radiobiological evaluation of a method for planning target volume generation dependent on organ-at-risk exclusions in magnetic resonance.
Clinical implementation of magnetic resonance imaging guided adaptive radiotherapy for localized prostate cancer  Shyama U. Tetar, Anna M.E. Bruynzeel,
Technical Innovations and Patient Support in Radiation Oncology
Jesse Conterato, BA&Sc. RSNA 2016
Principles of Radiation Therapy
Presentation transcript:

The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates, P.A. Naples, Florida

Frameless Radiosurgery Robotics Image Guidance Advanced Treatment Planning CyberKnife Technology

Precise control limits dose to the rectal wall and urethra Prostate Radiosurgery Image courtesy of San Diego CyberKnife Center

Patient lies comfortably on the couch while the CyberKnife robot moves, images and treats. Treatments typically last 1 hour Most patients require no sedation allowing them to depart at the completion of their treatment CyberKnife Treatment Delivery

Radiation Options ConvenienceInvasiveToxicityEfficacy IMRTLowNoModHigh LDR BrachyTx HighYes X 1ModHigh HDR BrachyTx ModerateYes X 2ModHigh CKHighNoVery LowTBD

PATIENT DRIVEN NON-INVASIVE MINIMAL SIDE EFFECTS MINIMAL DISRUPTION OF LIFE EFFICACY

Precise control limits dose to the rectal wall and urethra Automatic correction for target motion during treatment Prostate Radiosurgery Footage courtesy of St. Anthony’s Hospital

Prostate PTV: gland expanded 5 mm in each direction except posteriorly where it is expanded 3 mm

Prostate comparison: axial & sagittal 40 and 25 mm colls40 mm coll

Prostate comparison: urethra 40 mm coll40 and 25 mm colls 18.7% vol at 90% dose 30.8% vol at 90% dose

Prostate comparison: bladder 12.2% vol at 60% dose 16.7% vol at 60% dose 40 mm coll 40 and 25 mm colls

Prostate comparison: rectum 40 mm coll40 and 25 mm colls 20.5% vol at 60% dose 11.2% vol at 60% dose

Basic Demographics Ages 62 to 85 Stage cT1cNoMo to cT2bNoMo All patients treated between 12/07/2004 and 12/31/2007 Total number of Patients = 213

PSA Response to Cyberknife

IPSS Scores After Cyberknife SBRT

RAS and SHIM Scores after Cyberknife SBRT

Summary Cyberknife is a new and innovative treatment delivery technique for prostate cancer. Cyberknife monotherapy produces an early decline of PSA’s in low risk patients. The acute toxicity of Cyberknife monotherapy is very minimal compared to other radiation treatments. Cyberknife therapy is a noninvasive and convenient treatment option for patients with early stage prostate cancer. Prostate cancer patients treated with Cyberknife should continued to be enrolled and followed in research protocols, and the data collectively analyzed.